No abstract

T h e re are an increasing body of evidences fro m clinical trials that associate type 2 diabetes with c a rdiovascular disease, especially since the majority of those patients die from a card i o v a s c u l a r disease and macrovascular complications. MEDIFAM J. M. MILLARUELO TRILLO ET AL MEDIFAM 2002; 12 (8): 508-514 509 65 Palabras clave: Diabetes mellitus tipo 2. Glucemia postprandial. Enfermedad card i o v a s c u l a r. Dislipemia. Aterosclerosis. Nateglinida.spikes, could offer a good therapeutical option to manage patients with type 2 diabetes.